Presentation is loading. Please wait.

Presentation is loading. Please wait.

Early Versus Deferred Treatment With Combined Fludarabine, Cyclophosphamide and Rituximab (FCR) Improves Event-Free Survival In Patients With High-Risk.

Published byMargarethe Jaeger Modified over 6 years ago

Similar presentations

Presentation on theme: "Early Versus Deferred Treatment With Combined Fludarabine, Cyclophosphamide and Rituximab (FCR) Improves Event-Free Survival In Patients With High-Risk."— Presentation transcript:

1 Early Versus Deferred Treatment With Combined Fludarabine, Cyclophosphamide and Rituximab (FCR) Improves Event-Free Survival In Patients With High-Risk Binet Stage A Chronic Lymphocytic Leukemia – First Results Of a Randomized German-French Cooperative Phase III Trial by Carmen D Schweighofer, Florence Cymbalista, Carolin Müller, Raymonde Busch, Raphael Porcher, Petra Langerbeins, Bruno Cazin, Anna-Maria Fink, Brigitte Dreyfus, Stefan Ibach, Stéphane Leprêtre, Kirsten Fischer, Ursula Vehling-Kaiser, Barbara Eichhorst, Manuela A. Bergmann, Stephan Stilgenbauer, Hartmut Döhner, Veronique Leblond, Michael Hallek, and Vincent Levy Blood Volume 122(21): November 15, 2013 ©2013 by American Society of Hematology

2 Kaplan-Meier survival functions for EFS in 100 HR-FCR versus 101 HR-W&W patients.
Florence Cymbalista et al. Blood 2013;122:524 ©2013 by American Society of Hematology

Download ppt "Early Versus Deferred Treatment With Combined Fludarabine, Cyclophosphamide and Rituximab (FCR) Improves Event-Free Survival In Patients With High-Risk."

Similar presentations

What is the Optimal Approach to CLL, BR vs. FCR/FR?

What is the Optimal Approach to CLL, BR vs. FCR/FR?
Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial by Stephan Stilgenbauer, Andrea Schnaiter, Peter Paschka,

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial by Stephan Stilgenbauer, Andrea Schnaiter, Peter Paschka,
Agne Paner, MD Assistant professor of Medicine RUSH University Medical Center.

Agne Paner, MD Assistant professor of Medicine RUSH University Medical Center.
Copyright © 2011 Research To Practice. All rights reserved. Interest in Topics Related to the Treatment of Patients with CLL (Percent Responding 9 or 10)

Copyright © 2011 Research To Practice. All rights reserved. Interest in Topics Related to the Treatment of Patients with CLL (Percent Responding 9 or 10)
Lessons from the CLL8 study Adapted from Hallek, oral presentation, ASH 2008 FCR is superior to FC in most cytogenetic subgroups with regard to: Response.

Lessons from the CLL8 study Adapted from Hallek, oral presentation, ASH 2008 FCR is superior to FC in most cytogenetic subgroups with regard to: Response.
Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia by Natali Pflug, Jasmin Bahlo, Tait D. Shanafelt, Barbara.

Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia by Natali Pflug, Jasmin Bahlo, Tait D. Shanafelt, Barbara.
Frontline Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Shows Superior Efficacy in Comparison to Bendamustine.

Frontline Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Shows Superior Efficacy in Comparison to Bendamustine.
Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia by Alessandra Ferrajoli,

Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia by Alessandra Ferrajoli,
Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) versus Bendamustine and Rituximab (BR) in Previously Untreated and.

Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) versus Bendamustine and Rituximab (BR) in Previously Untreated and.
Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,
The clinical significance of tumor necrosis factor-α plasma level in patients having chronic lymphocytic leukemia by Alessandra Ferrajoli, Michael J. Keating,

The clinical significance of tumor necrosis factor-α plasma level in patients having chronic lymphocytic leukemia by Alessandra Ferrajoli, Michael J. Keating,
Summary Author: Dr. C. Tom Kouroukis, MD MSc FRCPC

Summary Author: Dr. C. Tom Kouroukis, MD MSc FRCPC
Geisler C et al. Proc ASH 2011;Abstract 290.

Geisler C et al. Proc ASH 2011;Abstract 290.
Rituximab, fludarabine, and cyclophosphamide versus fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia: A systematic review.

Rituximab, fludarabine, and cyclophosphamide versus fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia: A systematic review.
Circ Cardiovasc Interv

Circ Cardiovasc Interv
VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome.

VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome.
Increased Risk of Chronic Graft-Versus-Host Disease, Obstructive Bronchiolitis, and Alopecia With Busulfan Versus Total Body Irradiation: Long-Term Results.

Increased Risk of Chronic Graft-Versus-Host Disease, Obstructive Bronchiolitis, and Alopecia With Busulfan Versus Total Body Irradiation: Long-Term Results.
Alternate designs for conduct and analysis of phase I cancer trials

Alternate designs for conduct and analysis of phase I cancer trials
WHAT IS THE BEST Front-Line REGIMEN for Patients With CLL

WHAT IS THE BEST Front-Line REGIMEN for Patients With CLL
Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,

Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,

Similar presentations

Ads by Google